Verona Pharma plc (NASDAQ:TARA) Major Shareholder Randall Marshall Sells 2,516 Shares

Share on StockTwits

Verona Pharma plc (NASDAQ:TARA) major shareholder Randall Marshall sold 2,516 shares of Verona Pharma stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $26.42, for a total value of $66,472.72. Following the transaction, the insider now directly owns 613,197 shares of the company’s stock, valued at approximately $16,200,664.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Randall Marshall also recently made the following trade(s):

  • On Monday, July 27th, Randall Marshall sold 338 shares of Verona Pharma stock. The stock was sold at an average price of $26.08, for a total value of $8,815.04.
  • On Friday, July 24th, Randall Marshall sold 2,343 shares of Verona Pharma stock. The stock was sold at an average price of $26.53, for a total value of $62,159.79.
  • On Wednesday, July 22nd, Randall Marshall sold 1,372 shares of Verona Pharma stock. The stock was sold at an average price of $26.73, for a total value of $36,673.56.
  • On Friday, July 17th, Randall Marshall sold 1,601 shares of Verona Pharma stock. The stock was sold at an average price of $26.66, for a total value of $42,682.66.
  • On Monday, July 20th, Randall Marshall sold 4,330 shares of Verona Pharma stock. The stock was sold at an average price of $26.79, for a total value of $116,000.70.
  • On Monday, July 13th, Randall Marshall sold 2,145 shares of Verona Pharma stock. The stock was sold at an average price of $27.13, for a total value of $58,193.85.
  • On Friday, July 10th, Randall Marshall sold 2,659 shares of Verona Pharma stock. The stock was sold at an average price of $27.41, for a total value of $72,883.19.

Shares of NASDAQ:TARA opened at $24.94 on Friday. Verona Pharma plc has a 1 year low of $8.80 and a 1 year high of $67.08. The business’s 50-day moving average price is $28.93.

Verona Pharma (NASDAQ:TARA) last issued its earnings results on Wednesday, May 13th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($1.40). As a group, research analysts expect that Verona Pharma plc will post -2.59 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on the company. Guggenheim started coverage on Verona Pharma in a research note on Wednesday. They set a “buy” rating and a $50.00 price target for the company. Zacks Investment Research raised shares of Verona Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, July 15th.

Several large investors have recently modified their holdings of TARA. Ikarian Capital LLC purchased a new position in Verona Pharma in the 1st quarter worth approximately $10,368,000. DRW Securities LLC purchased a new position in Verona Pharma in the 1st quarter worth approximately $3,071,000. Perceptive Advisors LLC purchased a new position in Verona Pharma in the 1st quarter worth approximately $184,000. Citigroup Inc. purchased a new position in Verona Pharma in the 1st quarter worth approximately $43,000. Finally, Victory Capital Management Inc. purchased a new position in Verona Pharma in the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 67.70% of the company’s stock.

About Verona Pharma

ArTara Therapeutics, Inc develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.

Recommended Story: The primary rules of Elliott Wave theory

Insider Buying and Selling by Quarter for Verona Pharma (NASDAQ:TARA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Envestnet Asset Management Inc. Sells 209,720 Shares of Caleres Inc
Envestnet Asset Management Inc. Sells 209,720 Shares of Caleres Inc
Envestnet Asset Management Inc. Raises Stake in Monmouth R.E. Inv. Corp.
Envestnet Asset Management Inc. Raises Stake in Monmouth R.E. Inv. Corp.
Sunstone Hotel Investors Inc  Shares Sold by Envestnet Asset Management Inc.
Sunstone Hotel Investors Inc Shares Sold by Envestnet Asset Management Inc.
Momenta Pharmaceuticals, Inc.  SVP Sells $1,113,979.50 in Stock
Momenta Pharmaceuticals, Inc. SVP Sells $1,113,979.50 in Stock
United Continental Holdings Inc  Shares Sold by Janney Montgomery Scott LLC
United Continental Holdings Inc Shares Sold by Janney Montgomery Scott LLC
Home Bancshares  Trading 6% Higher
Home Bancshares Trading 6% Higher


© 2006-2020 Ticker Report